Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407363 | 0.92 | CNR1 (0.37) | CNR1RAB9AFAAHFFAR4HSD11B1 | |
| SCHEMBL2406016 | 0.89 | SYK (0.38) | CNR1RAB9ASMN1; SMN2FFAR4PIM2 | |
| SCHEMBL2411876 | 0.89 | CNR1 (0.41) | CNR1FAAHFFAR4PIM2 | |
| SCHEMBL2405682 | 0.89 | KMO (0.38) | CNR1KMT2AFFAR4KMO | |
| SCHEMBL2407342 | 0.89 | DKK1 (0.41) | CNR1RAB9ASMN1; SMN2FFAR4 | |
| SCHEMBL2411932 | 0.88 | SMN1; SMN2 (0.43) | CNR1SMN1; SMN2FFAR4 | |
| SCHEMBL2405737 | 0.88 | FFAR1 (0.36) | CNR1FAAHFFAR4PIM2 | |
| SCHEMBL2407041 | 0.87 | NPC1 (0.42) | CNR1RAB9AFFAR4 | |
| SCHEMBL2405723 | 0.87 | FFAR4 (0.41) | CNR1FFAR4PIM2 | |
| SCHEMBL2407416 | 0.87 | FFAR4 (0.36) | CNR1RAB9AFFAR4CNR2PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | CNR1 39/4885RAB9A 1287/4885SMN1; SMN2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.